With a buy­out, planned spin­out and late-stage read­outs, GSK promis­es this will be a land­mark year

Glax­o­SmithK­line CEO Em­ma Walm­s­ley has the Q1 sales num­bers to start off what she says will be a land­mark year. But de­liv­er­ing on the rest of the year might not be so easy.

So far, the num­bers are in her fa­vor. The UK phar­ma claimed Q1 sales of just over $12.2 bil­lion, beat­ing out sales es­ti­mates that orig­i­nal­ly placed the phar­ma’s quar­ter­ly sales at around $11.5 bil­lion and up 32% year over year. Their bio­phar­ma unit record­ed $8.9 bil­lion in sales, an in­crease of 40% over­all across its di­vi­sions of spe­cial­ty med­i­cines, on­col­o­gy and vac­cines. Ex­ecs fur­ther elab­o­rat­ed that it was the suc­cess of its Covid-19 an­ti­body Xe­vudy that drove the num­bers up, say­ing in a call with an­a­lysts and in­vestors that growth was 15% with­out Xe­vudy. GSK’s con­sumer health­care unit made the re­main­ing $3.3 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER